Department of Medicine, Université Laval, Hôpital Hôtel-Dieu de Québec, Quebec, QC, Canada.
Int J Dermatol. 2010 Dec;49(12):1368-75. doi: 10.1111/j.1365-4632.2010.04660.x.
Psoriasis is a chronic inflammatory disease associated with comorbidities and decreased quality of life. This survey is aimed to better understand the impact of disease on Canadian patients, and to examine awareness and use of available treatment options.
An online survey was conducted using a consumer panel. Eligible subjects reported diagnoses of psoriasis and moderate/severe/very severe plaque psoriasis within the past 5 years, and either: psoriasis covering ≥ 3% of body surface area; psoriasis on a sensitive area, or current use of systemic and/or phototherapy or light therapy for psoriasis.
A total of 514 panelists completed the survey; 65% reported current moderate/severe/very severe psoriasis. Awareness of available treatment options ranged from 98% for prescription topical agents to 75% for photo/light therapy, and < 50% for prescription oral (49%) or injectable (35%) medications. A total of 92% of respondents had been treated with and 61% were currently taking prescription topical agents. Photo/light therapy had been used by 38% and was currently used by 7% of respondents. Prescribed oral medication had been taken by 25% and was currently used by 8%. Few subjects had been treated with injectables in the past (10%) or currently (5%). Overall, 24% of respondents were very satisfied with their current treatment. A total of 63% of respondents taking injectables were very satisfied, compared with 38% of those taking prescribed oral medication and 21% of those receiving photo/light therapy.Conclusions Most respondents with moderate to severe psoriasis were unaware of all treatment options; systemic treatments were not commonly utilized. Treatment satisfaction rates were low, highlighting the need to ensure greater patient education on and use of available therapeutic options.
银屑病是一种慢性炎症性疾病,与合并症和生活质量下降有关。本调查旨在更好地了解疾病对加拿大患者的影响,并研究现有治疗方案的认知和使用情况。
使用消费者小组进行了在线调查。合格的受试者报告在过去 5 年内患有银屑病和中度/重度/非常严重的斑块型银屑病,且满足以下条件之一:银屑病皮损面积≥3%;皮损位于敏感部位,或目前正在使用全身和/或光疗或光化学疗法治疗银屑病。
共有 514 名小组成员完成了调查;65%报告目前患有中度/重度/非常严重的银屑病。对现有治疗方案的认知范围从处方外用制剂的 98%到光疗/光化学疗法的 75%,而处方口服(49%)或注射(35%)药物<50%。92%的受访者接受过治疗,61%目前正在使用处方外用制剂。38%的受访者使用过光疗/光化学疗法,目前有 7%的受访者正在使用。25%的受访者曾服用过口服药物,目前有 8%的受访者正在服用。过去(10%)或目前(5%)很少有患者接受过注射治疗。总体而言,24%的受访者对当前的治疗非常满意。接受注射治疗的受访者中,非常满意的比例为 63%,而接受口服药物治疗的受访者中,非常满意的比例为 38%,接受光疗/光化学疗法的受访者中,非常满意的比例为 21%。
大多数中重度银屑病患者对所有治疗方案均不了解;全身治疗并不常用。治疗满意度低,这突显了需要确保对患者进行更好的教育,并使用现有的治疗选择。